A one-year prospective, randomized, placebo-controlled, double-blind, phase II/III safety trial of combination therapy with IFN beta 1a [interferon beta-1a] (Avonex) and mycophenolate mofetil (Cellcept) in early multiple sclerosis

Trial Profile

A one-year prospective, randomized, placebo-controlled, double-blind, phase II/III safety trial of combination therapy with IFN beta 1a [interferon beta-1a] (Avonex) and mycophenolate mofetil (Cellcept) in early multiple sclerosis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Interferon beta-1a (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Oct 2007 Results have been presented.
    • 25 May 2007 Status changed from in progress to completed.
    • 29 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top